SLC35B4 Activators
SLC35B4 Activators comprise a selection of chemical compounds that indirectly enhance the functional activity of SLC35B4 through various signaling mechanisms and modifications of the intracellular environment. Forskolin and 8-Bromo-cAMP elevate cAMP levels, thereby activating PKA, which can lead to phosphorylation events that potentially enhance SLC35B4 activity by modulating the cellular environment in which it operates. Ionomycin and A23187 both act as calcium ionophores, increasing intracellular calcium levels, which could indirectly affect SLC35B4 by activating calcium-dependent signaling pathways that modulate the transporter's activity. PMA serves as a PKC activator, leading to phosphorylation of proteins that could influence SLC35B4 function by altering membranedynamics. Furthermore, Okadaic Acid, by inhibiting the dephosphorylation activity of protein phosphatases PP1 and PP2A, could maintain a phosphorylated state of regulatory proteins, indirectly enhancing SLC35B4 activity. Genistein, as a tyrosine kinase inhibitor, and LY294002, a PI3K inhibitor, alter phosphorylation cascades and membrane-associated signaling, respectively, which may shift the cell's regulatory mechanisms in favor of SLC35B4 activation.
The activity of SLC35B4 is also influenced by U73122, which inhibits phospholipase C and may lead to an accumulation of PIP2 in the membrane, potentially impacting SLC35B4's activity by modifying its local lipid environment. 2-APB, by modulating IP3 receptors and calcium entry, can affect calcium-dependent signaling pathways, indirectly contributing to the enhancement of SLC35B4 function. Sphingosine-1-phosphate engages with its receptors to trigger downstream signaling pathways like AKT, ERK, and Rac, which may create a favorable context for SLC35B4 activation through complex network interactions. Lastly, W-7 Hydrochloride, as a calmodulin antagonist, disrupts calmodulin-dependent processes, potentially leading to an indirect increase in SLC35B4 activity by affecting the phosphorylation state of proteins within its regulatory framework. Collectively, these SLC35B4 Activators, through their targeted effects on cellular signaling, foster the enhancement of SLC35B4 mediated functions without necessitating upregulation of its expression or direct activation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can lead to the activation of PKA. PKA can phosphorylate various proteins and factors that may indirectly enhance the activity of SLC35B4 by modulating the cellular environment that SLC35B4 operates within, particularly if PKA influences the lipid composition of membranes where SLC35B4 is localized. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that elevates intracellular calcium levels, potentially modulating calcium-dependent signaling pathways. Increased calcium signaling can modify the activity of membrane transporters including SLC35B4 by altering their regulatory environment. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which could lead to subsequent phosphorylation events. These phosphorylations can alter the activity of SLC35B4 indirectly by changing the membrane dynamics or by phosphorylation of associated regulatory proteins. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
Similar to Forskolin, 8-Bromo-cAMP is a cAMP analog that activates PKA. This activation can lead to a cascade of phosphorylations that might enhance the functional activity of SLC35B4 by altering its regulatory mechanisms or transport activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is another calcium ionophore, which increases intracellular calcium levels, potentially affecting calcium-dependent processes and indirectly enhancing SLC35B4 function by affecting the transporter's environment. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This can indirectly enhance the activity of SLC35B4 by preventing dephosphorylation of proteins that regulate its activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor; by inhibiting these kinases, it can affect various signaling pathways that may indirectly enhance the activity of SLC35B4 by altering the phosphorylation state of proteins involved in its regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which can lead to alterations in the PI3K/AKT signaling pathway. This may result in an indirect enhancement of SLC35B4 activity by changing the membrane dynamics where SLC35B4 functions. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
2-APB modulates IP3 receptors and store-operated calcium entry. By affecting calcium signaling, 2-APB could indirectly enhance the activity of SLC35B4 through modulation of calcium-dependent regulatory mechanisms. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate is a bioactive lipid that can activate sphingosine-1-phosphate receptors and subsequently influence the AKT, ERK, and Rac signaling pathways. This can indirectly enhance the activity of SLC35B4 by affecting the transporter's regulatory network. | ||||||